A multicenter, randomized, observation-controlled clinical trial to evaluate the efficacy and safety of thymalfasin adjuvant therapy in patients with HBV-related HCC after curative resection - First announcement of the protocol

Expert Opinion on Biological Therapy

Volumn 15, Issue , 2015, Pages 133-137

  Qiu, Shuang Jian ^a   Zhou, Zhong Guo ^b   Shen, Feng ^c   Li, Ai Jun ^c   Chen, Min Shan ^b   Ying, Min Gang ^d   Chen, Zhong ^e   Zhang, Yi Xin ^f   Sun, Hui Chuan ^a   Fan, Jia ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d Fujian Provincial Maternity Hospital   (China)

^e NANTONG UNIVERSITY   (China)

^f NANTONG TUMOR HOSPITAL   (China)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Immune regulator; Thymalfasin (thymosin 1 Ta1)

Indexed keywords

ENTECAVIR; LAMIVUDINE; SORAFENIB; THYMOSIN ALPHA1; THYMOSIN;

CANCER ADJUVANT THERAPY; CANCER SURGERY; CHEMOEMBOLIZATION; CHINA; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; METHODOLOGY; MULTICENTER STUDY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR RECURRENCE; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; CHINA; HEPATECTOMY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RESEARCH DESIGN; THYMOSIN; TREATMENT OUTCOME;

EID: 84965084666     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1039979     Document Type: Editorial

References (21)

1. World Health Organization. International agency for research on cancer. GLOBOCAN. 2012. Available from: http://globocan. iarc.fr/Pages/fact_sheets_population.aspx
2. El-Serag HB. Hepatocellular Carcinoma. N Engl J Med 2011;365:1118-12
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55
4. Sawada Y, Ofuji K, Sakai M, et al. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives[M]. INTECH Open Access Publisher, Rijeka,Croatia; 2013
5. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103(11):4232-9
6. Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 2006;108(7):2265-74
7. Romani L, Bistoni F, Montagnoli C, et al. Thymsoin alpha 1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci 2007;1112:326-38
8. Romani L, Moretti S, Fallarino F, et al. Jack of all trades: thymosin alpha 1 and its pleiotropy. Ann N Y Acad Sci 2012;1269:1-6.
9. Giuliani C, Napolitano G, Mastino A, et al. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol 2000;30(3):778-86
10. SinibaldiVallebona P, Pierimarchi P, Moroni G, et al. Thymalfasin upregulates tumor antigen expression in colorectal cancer cells. XXXth Meet Int Soc Oncodevel Biol Med 2002
11. Garaci E, Pica F, Serafino A, et al. Thymosin alpha 1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci 2012;1269:11-18
12. Stefanini GF, Foschi FG, Castelli E, et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology 1998;45:209-15
13. Zhang WJ. Transcatheter arterial chemotherapy and embolization plus thymosin alpha 1 for treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2004;15:A401
14. Li ZS. HCC patients treated with TACE combined with thymalfasin: one year follow up. Paper presented at: Shanghai International Oncology Conference; 2001
15. Cheng S, Wu M, Chen H, et al. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha 1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology 2004;51:1445-7
16. Cheng S, Wu M, Chen H, et al. Transcatheter hepatic arterial chemoembolization and thymosin in postoperative treatment of hepatocellular carcinoma. Chinese J Oncol 2004;26(5):305-7
17. Cheng S, Wu M, Chen H, et al. Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B. Chinese J Oncol 2005;27(2):114-16.
18. Cheng S, Ding G, Shi J, et al. Role of antivirus therapy in treatment of hepatocellular carcinoma with chronic hepatitis B infection. Chinese-Ger J Clin Oncol 2005;4(6):330-3
19. Cheng S, Wu M, Chen H, et al. Antiviral therapy using lamivudine and thymosin alpha 1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology 2006;53:249-52
20. Gish RG, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int 2009;3(3):480-9
21. Gu X, Jiang Z, Yang M. Efficacy of sorafenib with thymosin a1 for patients with advanced hepatocellular carcinoma [J]. Jiangsu Med J 2010;21:004